What is Myriad Genetics's market cap?

Myriad Genetics (MYGN) has a market capitalization of $514.7M and trades on NASDAQ.

What is Myriad Genetics's revenue and profitability?

Myriad Genetics generated $829.0M in trailing twelve-month revenue with a net loss of $399.9M, representing a net margin of -48.2%. Gross margin stands at 70.0%. These figures are based on the Q1 2026 filing.

Who are Myriad Genetics's competitors?

Myriad Genetics's key competitors include Fulgent Genetics, Inc., Natera, Inc., NeoGenomics, Inc., and others. These companies compete in similar markets and product categories.

Who does Myriad Genetics partner with?

Myriad Genetics's notable partners include PATHOMIQ, Inc., SOPHiA GENETICS S.A., Illumina, Inc., and others.

Where is Myriad Genetics headquartered?

Myriad Genetics is headquartered in United States of America and employs approximately 2,700 people. It has been publicly traded since 1995.

Myriad Genetics

MYGN

Myriad Genetics is a leading molecular diagnostics and precision medicine company that develops and commercializes genetic tests across oncology, women's health, and mental health.

Market cap

$514.74M+37.9%

Revenue$829.0M-0.3%

Net income-$399.9M-294%

EPS (diluted)-$4.29-283%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 5, 2026

Revenue$200.4MMiss by $2.0M EPS-$0.09Miss by $0.03

Read the full report

Next report

Jul 30, 2026 (Tomorrow)

Revenue estimate$206.0M

EPS estimate-$0.03

Financials

Q1 2026

Income statement

See full

Revenue$200.4M+2.3%

Gross profit$137.6M+2.5%

Operating income-$30.7M-5.9%

Net income-$34.1M-34,000%

EPS (diluted)-$0.36—

Balance sheet

See full

Cash & equivalents$126.0M+24.8%

Total debt$211.5M+34.2%

Total equity$337.4M-52.1%

Total assets$673.7M-33.0%

Cash flow

See full

Operating cash flow-$15.7M+3.7%

Valuation & ratios

Valuation

See full

Market cap$514.74M+37.9%

Enterprise value$600.24M+26.5%

P/S0.6×+0.1×

Profitability

See full

Gross margin70%0.0pp

Operating margin-46.9%-88.3pp

Net margin-48.2%-72.9pp

Returns & leverage

See full

Return on equity-76.7%-98.4pp

Debt / equity0.6×+0.4×

Current ratio2.4×+0.5×

Segments

By product

See full

Cancer Care Continuum$120.2M—

Prenatal Health$41.9M—

Mental Health$38.3M—

Competitors

By market cap

Natera, Inc.$37.0B+96.1%

Quest Diagnostics$25.6B+36.3%

Labcorp Holdings$24.7B+13.8%

Guardant Health$19.3B+252%

Tempus AI, Inc.$7.7B-28.0%

NeoGenomics$1.7B+106%

Fulgent Genetics, Inc.$556.1M+1.4%

Myriad Genetics$514.7M+27.5%

By revenue growth

Tempus AI, Inc.+69.8%

Guardant Health+39.6%

Natera, Inc.+36.6%

NeoGenomics+11.2%

Quest Diagnostics+9.9%

Fulgent Genetics, Inc.+9.5%

Labcorp Holdings+7.3%

Myriad Genetics-0.3%

By net margin

Quest Diagnostics9.19%+0.2pp

Labcorp Holdings6.66%+1.1pp

NeoGenomics-6.77%+8.3pp

Natera, Inc.-14.61%-3.2pp

Tempus AI, Inc.-22.2%+66.1pp

Fulgent Genetics, Inc.-23.04%-9.1pp

Guardant Health-40.1%+13.7pp

Myriad Genetics-48.24%-36.0pp

Profile

Myriad Genetics is a leading molecular diagnostics and precision medicine company that develops and commercializes genetic tests across oncology, women's health, and mental health. The company provides actionable genomic insights to help patients and healthcare providers assess disease risk, guide treatment decisions, and enable earlier detection of conditions. Its core value proposition centers on improving patient outcomes and lowering healthcare costs through personalized molecular data and technology-enabled laboratory operations.

Competitive position

A pioneer in DNA-based cancer diagnostics and a market leader in hereditary cancer and pharmacogenomic mental health testing.

GeographiesUnited States, Japan, Europe, Asia-Pacific

Customer segmentsHealthcare providers, Biopharmaceutical companies, Patients, Payors

Business modelLaboratory testing services, Direct-to-consumer testing, B2B biopharma services

SuppliersNext-generation sequencing (NGS) equipment manufacturers, Laboratory reagent suppliers, Bioinformatics software providers, Academic research institutions

CustomersHospitals and health systems, Independent physician practices, Biopharmaceutical clinical trial sponsors, Direct-to-consumer patients

CountryUnited States of America

Listed1995

Employees2.7K

CEOSamraat S Raha

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websitemyriad.com

FilingsSEC EDGAR

Ask your AI about Myriad Genetics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Myriad Genetics's market cap?: Myriad Genetics (MYGN) has a market capitalization of $514.7M and trades on NASDAQ.
What is Myriad Genetics's revenue and profitability?: Myriad Genetics generated $829.0M in trailing twelve-month revenue with a net loss of $399.9M, representing a net margin of -48.2%. Gross margin stands at 70.0%. These figures are based on the Q1 2026 filing.
Who are Myriad Genetics's competitors?: Myriad Genetics's key competitors include Fulgent Genetics, Inc., Natera, Inc., NeoGenomics, Inc., and others. These companies compete in similar markets and product categories.
Who does Myriad Genetics partner with?: Myriad Genetics's notable partners include PATHOMIQ, Inc., SOPHiA GENETICS S.A., Illumina, Inc., and others.
Where is Myriad Genetics headquartered?: Myriad Genetics is headquartered in United States of America and employs approximately 2,700 people. It has been publicly traded since 1995.